Both conditions often show narrowing in the brain's veinsa sign typically linked to increased pressure within the skull
46 That dedicated kidney outcomes study, involving over 3500 patients with both T2D and established chronic kidney disease, demonstrated that once-weekly subcutaneous semaglutide 1.0 mg significantly reduced the primary composite renal outcome (including kidney failure onset, a 50% persistent decline in estimated glomerular filtration rate (eGFR), or renal/cardiovascular death) compared with placebo
Wanting to increase the dosage to break through a plateau Another common theme Katz cautions against is the desire to increase the dose to reduce appetite even further in order to shatter a plateau
This is something I hear quite frequently from patients with hyperthyroidism and its worth a discussion
As insurance coverage expands and out-of-pocket costs fall, use of GLP-1 drugs is likely to increase further, especially for weight loss
As with most dietary supplements, the research on drug interactions with glutathione is incomplete